"PHA's research program has yielded an explosion of understanding about PH that was not known before."
- John Newman, MD, Vanderbilt University Medical Center

Twenty years ago there were no pulmonary hypertension treatments available. Through focused research there are now twelve PH-specific treatments with more in development. But we know that your ultimate wish is for a cure, and that is why PHA will continue to support the work of researchers until the day when no one suffers from PH.

PHA’s Research Program

In just a little under a decade, PHA’s Research Program has committed more than $14 million for PH research by leveraging partnerships with the National Heart, Lung, and Blood Institute (NHLBI) and the American Thoracic Society (ATS). We have supported over 49 promising researchers through four independently reviewed, cutting-edge research programs.

Read more about PHA’s Research Program

Learn more

Current Treatments

PHA’s Scientific Leadership Council’s Education Committee has put together comprehensive factsheets on all the treatments available for pulmonary hypertension. Read more about current treatments

Research Corner in Pathlight

Every issue of PHA’s quarterly print newsletter Pathlight features a Research Corner with information about some of the latest research. Read more


Pulmonary Hypertension Research News
PHA Endorses CHEST Treatment Guidelines

The American College of Chest Physicians (CHEST) recently released guidelines for the management and treatment of pulmonary arterial hypertension (PAH) in adults, Pharmacological Therapy for Pulmonary Arterial Hypertension in Adults: CHEST Guideline and Expert Panel Report, in the CHEST Journal. The guidelines are free to view for clinicians, and provide the latest and most accurate treatment guidelines for PAH.

The Pulmonary Hypertension Association (PHA) endorses these guidelines and sees them as a step in the right direction. “Many times physicians are not clearly informed on the latest ways to treat PAH,” said Rino Aldrighetti, PHA President and CEO. “These guidelines help physicians understand the broad range of therapies available and the need for more research to create more.”

The CHEST Guideline and Expert Panel Report provides 79 recommendations and expert consensus statements aimed at assisting physicians in the management of PAH using the latest drug therapies. The guidelines were reviewed and endorsed by the PHA Scientific Leadership Council.

Read the guidelines

Thursday, August 28, 2014 4:27:00 PM

Less Invasive Alternative for Treating Severe Pulmonary Hypertension in Infants

Health e Galaxy - Subcutaneous treprostinil improves outcomes in selected infants with severe pulmonary hypertension and chronic lung disease (CLD) of infancy that have not responded adequately to conservative therapies, researchers say. This is a report of one center’s experience with an extremely small number of carefully selected patients.

One of the co-authors on this paper is Erika Berman-Rosenzweig, MD, a member of PHA's Board of Trustees and Scientific Leadership Council. Read article

Sunday, July 13, 2014 9:48:00 AM

Hidden Origins of Pulmonary Hypertension Revealed by Network Modeling

Medical Xpress - In a groundbreaking study, researchers from Brigham and Women's Hospital (BWH) have identified a related family of molecules believed to be a major root cause of pulmonary hypertension, a deadly vascular disease with undefined origins. This is one of the first studies to leverage advanced computational network modeling to decipher the molecular secrets of this complex human disease.

The study is published online June 24, 2014 in The Journal of Clinical Investigation. The senior corresponding author, Stephen Y. Chan, MD, PhD, BWH Divisions of Cardiovascular Medicine and Network Medicine, was a 2010 recipient of PHA's K08 Supplemental Award. Read article

Saturday, July 12, 2014 9:51:00 AM

Possible New Type of Targeted Therapy for Pulmonary Hypertension

Reuters - Actelion Pharmaceuticals US, Inc. released today the initial, positive results from the Phase III GRIPHON study of selexipag in 1,156 patients with pulmonary arterial hypertension (PAH). Selexipag is the first non-prostacyclin analogue that acts as a stimulator for the prostaglandin receptor (IP). Read article

Monday, June 16, 2014 7:52:00 AM

New Treatment Fact Sheet on Macitentan

PHA's Scientific Leadership Council recently finalized their official fact sheet on macitentan (Opsumit®).

Read and download the new fact sheet

Saturday, June 14, 2014 7:55:00 AM


Woman having blood drawn

Participating in research & clinical trials helps gain information vital to progress toward a cure

Learn more about participating in research


Put your Members of Congress to work for you, their constituent. Ask them to support federal funding for PH research and education.

Advocate for PH research funding

Email Updates

Stay informed about current research, events, and more.

Sign up

Donate to Research

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

For the best viewing experience of this site, it is recommended that you use Internet Explorer 8 or 9 or Firefox.

© 2014 Pulmonary Hypertension Association. All Rights Reserved.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
    Privacy Policy   Virtual Tour of Website    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.®


The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.